Myasthenia Gravis

Condition Description

A weakness and rapid fatigue of muscles under voluntary control.

The condition is caused by a breakdown in communication between nerves and muscles.

Symptoms include weakness in the arm and leg muscles, double vision, and difficulties with speech and chewing.

Active Trials

Upcoming Trials

Past Trials

  • TRIAL TITLE: A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

    DESCRIPTION: The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

    SPONSOR: Immunovant Sciences GmbH

    INDICATION: Myasthenia Gravis

    STUDY PROTOCOL: RVT-1401-2002

    PHASE: 2a

    STATUS: Completed

    RECRUITING PATIENTS: No